GlobeNewsWire
29 Jun 2026, 20:01 UTC · 20w ago
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
Impact · against what's priced in
Nuvectis Pharma is initiating a public offering of common stock, which will result in immediate shareholder dilution. While the proceeds provide necessary runway for its NXP100, NXP200, and NXP900 programs, the negative impact of dilution typically outweighs the benefit of capital infusion for clinical-stage biotech stocks.
- NVCT−0.30
No priced-in read yet
- In context
The commencement of an underwritten public offering of common stock and the potential 15% over-allotment option create immediate share dilution for current investors.
Read from the article alone

Top 1 mover · tap to explore




